01What are FDA Category 1, 2 and 3 peptides?
The categories belong to FDA's interim policy for bulk substances that compounding pharmacies may use under Section 503A.
Category 1
Nominated with enough information to evaluate, no identified significant safety risk. May be compounded while FDA decides.
Category 2
Raises significant safety risks. FDA intends to act against compounders using them.
Category 3
Nominated without adequate supporting information. Cannot be evaluated until resubmitted.
02When can a bulk substance be used in 503A compounding?
A bulk substance can lawfully be used in 503A compounding only if it meets one of three tests.
A published compendial standard.
Already part of an FDA-approved product.
Added through notice-and-comment rulemaking after advisory-committee review.
03Does leaving Category 2 mean a peptide is approved?
No. In April 2026 twelve peptides left Category 2 after their nominations were withdrawn. That removed a red flag; it did not move them into Category 1 or onto the bulks list.
In July 2026 the advisory committee recommended six of them for the bulks list. That is advice, not a listing. In October 2026 HHS issued an interim enforcement-discretion policy for those six while rulemaking continues. Each step matters; none of them is FDA approval.
042026 status at a glance
| Peptide | Category 2 (2023) | Left Category 2 (Apr 2026) | PCAC (Jul 2026) | HHS interim policy (Oct 2026) |
|---|---|---|---|---|
| BPC-157 | Yes | Yes | Recommended | Covered |
| TB-500 | Yes | Yes | Recommended | Covered |
| KPV | Yes | Yes | Recommended | Covered |
| MOTS-c | Yes | Yes | Recommended | Covered |
| Semax | Yes | Yes | Recommended | Covered |
| Epitalon | Yes | Yes | Recommended | Covered |
| DSIP (emideltide) | Yes | Yes | Not recommended (press-reported) | Not covered |